CD39 is expressed by a wide range of cutaneous T-cell lymphomas.


Journal

Skin health and disease
ISSN: 2690-442X
Titre abrégé: Skin Health Dis
Pays: England
ID NLM: 9918227353706676

Informations de publication

Date de publication:
Apr 2024
Historique:
medline: 5 4 2024
pubmed: 5 4 2024
entrez: 5 4 2024
Statut: epublish

Résumé

CD39, an ectoenzyme in the immunosuppressive CD39/CD73/adenosine pathway, known to promote solid tumour outgrowth and spreading, was investigated in both skin and blood compartments of cutaneous T cell lymphomas. CD39 was overexpressed by peripheral blood T-cells in Sezary syndrome and mycosis fungoides, and in skin-infiltrating lymphocytes of Sezary syndrome, mycosis fungoides, subcutaneous panniculitis-like T-cell lymphoma and primary cutaneous CD30-positive lymphoproliferation. Our study emphasizes the interest in using CD39/CD73/adenosine pathway blocking agents for cutaneous T cell lymphomas treatment.

Identifiants

pubmed: 38577051
doi: 10.1002/ski2.334
pii: SKI2334
pmc: PMC10988668
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e334

Informations de copyright

© 2024 The Authors. Skin Health and Disease published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest.

Auteurs

Gilles Battesti (G)

Team 1 Human Immunology, Pathophysiology, Immunotherapy INSERM U976 Paris France.
Université Paris Cité IRSL Paris France.

Nicolas Thonnart (N)

Team 1 Human Immunology, Pathophysiology, Immunotherapy INSERM U976 Paris France.
Université Paris Cité IRSL Paris France.

Alizée Bozonnat (A)

Team 1 Human Immunology, Pathophysiology, Immunotherapy INSERM U976 Paris France.
Université Paris Cité IRSL Paris France.

Caroline Ram-Wolff (C)

Team 1 Human Immunology, Pathophysiology, Immunotherapy INSERM U976 Paris France.
Université Paris Cité IRSL Paris France.
Department of Dermatology Saint-Louis Hospital Paris France.

Adèle de Masson (A)

Team 1 Human Immunology, Pathophysiology, Immunotherapy INSERM U976 Paris France.
Université Paris Cité IRSL Paris France.
Department of Dermatology Saint-Louis Hospital Paris France.

Armand Bensussan (A)

Team 1 Human Immunology, Pathophysiology, Immunotherapy INSERM U976 Paris France.
Université Paris Cité IRSL Paris France.

Martine Bagot (M)

Team 1 Human Immunology, Pathophysiology, Immunotherapy INSERM U976 Paris France.
Université Paris Cité IRSL Paris France.
Department of Dermatology Saint-Louis Hospital Paris France.

Anne Marie-Cardine (A)

Team 1 Human Immunology, Pathophysiology, Immunotherapy INSERM U976 Paris France.
Université Paris Cité IRSL Paris France.

Maxime Battistella (M)

Team 1 Human Immunology, Pathophysiology, Immunotherapy INSERM U976 Paris France.
Université Paris Cité IRSL Paris France.
Department of Pathology Saint-Louis Hospital Paris France.

Classifications MeSH